Company Overview
Company Type: Private Company
Company Status: Reorganizing
Website: www.paladin-labs.com
Number of Employees: 403
Year Founded: 1983
Total Amount Raised (CAD mm)†: 6.00
Total Rounds of Funding**:1
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Paladin Labs Inc., researches, develops, acquires, in-licenses, markets, and distributes pharmaceutical products. It focuses on various therapeutic fields, such as urology, pain and central nervous system, women’s health, allergy, endocrinology, and dermatology. The company primarily offers Abstral for the management of breakthrough pain in patients with cancer; GlucaGen for emergency treatment of hypoglycemia in insulin-dependent diabetics; Oralair for the treatment of the symptoms of seasonal grass pollen allergic rhinitis; and Metadol for use as an analgesic in acute cancer pain, palliative care, and chronic pain disorders, as well as for the detoxification or maintenance treatment of opioid-dependent individuals. Its principal products also include Plan B (Levonorgestrel), an emergency contraceptive; Pollinex-R for the pre-seasonal immunotherapy of adults and children; Seasonale, an oral contraceptive; Silenor for the treatment and symptomatic relief of insomnia; Testim for testosterone replacement therapy in adult males; Twinject, a pre-filled auto-injector for emergency treatment of severe allergic reactions; and Tridural for moderate to moderately severe pain. In addition, the company researches and develops pharmaceuticals and medical devices as well as supplies vaccines to South Africa and countries comprising the South African Development Community region. Paladin Labs Inc. was formerly known as Geriatrx Pharmaceutical Corp. and changed its name to Paladin Labs Inc. in June 1995. The company was founded in 1983 and is headquartered in St-Laurent, Canada. As of February 28, 2014, Paladin Labs Inc. operates as a subsidiary of Paladin Labs Canadian Holding Inc. On August 16, 2022, Paladin Labs Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York. It is in joint administration with Endo International plc.

Financial Information (Currency: CAD, in mm) 
Total Revenue
276.8
Market Capitalization
2,949.9
EBITDA
92.9
EBIT
71.0
Cash & ST Invst.
291.1
P/Diluted EPS Before Extra
58.2x
Net Income
51.9
Total Debt
40.4
Price/Tang BV
10.5x
Capital Expenditure
(1.0)
Total Assets
617.7
Total Debt/EBITDA
0.4x
U.S. Number of Employees 2023
-
U.S. Number of Employees 2022
-
U.S. Last Year Employee Growth %
-
Currency in CAD in mm, LTM as of Dec-31-2013 TEV and Market Cap are calculated using a close price as of Feb-28-2014


Guidance Snapshot (Current Fiscal Year End: Dec-31-2013 | Currency: CAD)
Periodic Estimates
Current FQ
Guidance Current FQ
Current FY
Guidance Current FY
NTM
Revenue (mm)
-
-
-
255.00 - -
-






Key Professionals
Name
Title
Di Francesco, Livio
Interim General Manager and Vice President of Finance
Emblem, Susan Caroline
Vice President of Human Resources and Corporate Communications
Trempe, Isabelle
Vice President of Business Development


Primary Industry Classification
Pharmaceuticals


Primary Office Location
100 Boulevard Alexis Nihon Suite 600 | St-Laurent, QC | H4M 2P2 | Canada
Phone: 514-340-1112   Fax: 514-344-4675

Parent Company
Paladin Labs Canadian Holding Inc.

Prior Investors
BioCapital Investments Limited Partnership, Coller Capital Ltd., Information Venture Partners, Innovatech Grand Montreal, Investissement Québec, Investment Arm, Joddes Limited, Mawer Investment Management Ltd., Quorum Group of Companies, RBC Capital Partners, SGF Santé, Inc., Societe Generale de Financement du Quebec


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Triton Pharma Inc.
As of January 13, 2014, Triton Pharma Inc. was acquired by Paladin Labs Inc. Triton Pharma Inc. operates as a pharmaceutical marketing company that specializes in the commercialization of prescription drugs and natural products in Canada. The company offers products for gynecology/women's health, urology, and dermatology applications. Its product portfolio comprises prescription drugs available through pharmacies; and natural products available through pharmacies and its online store. The company was founded in 2001 and is based in Montreal, Canada. 

United States and Canada
Health Care Distributors
-
-
-
Allon Therapeutics, Inc., Substantially All Assets
As of July 16, 2013, substantially all assets of Allon Therapeutics, Inc. were acquired by Paladin Labs Inc.. Allon Therapeutics, Inc., Substantially All Assets comprises a biotechnology company that develops and markets central nervous system therapies.

United States and Canada
Biotechnology
-
-
-
ATIVA PHARMA S.A. de C.V.
ATIVA PHARMA S.A. de C.V. commercializes pharmaceuticals, medical devices, and healthcare products in Mexico. It offers low molecular weight heparins, monoclonal antibodies, and specialized medical devices for cardiovascular diseases; and drugs, diagnostics, food supplements, and ambulatory infusion devices and others for oncology diseases. The company also provides treatments of prediabetes; self-diagnostics for early warning; oral medication to reduce blood glucose levels; food supplements for the normalization of chemical imbalances and treatment of the disease; insulin and newer injectable medications; diabetically caused wound treatments to reduce risk of amputation and protection devices; and treatment against diabetic neuropathies and their resultant pain, to reduce glucose levels, and to prevent further nerve damage and pain. In addition, ATIVA PHARMA S.A. de C.V. offers brand name and generic drugs for nephrology/urology; drugs for enlarged prostate and sexual dysfunction; treatment of diseases of the kidney and the urinary tract; food additives for benign prostate hyperplasia, painful bladder syndrome, and other urological conditions; and treatments for female stress urinary incontinence, pelvic floor repair, post surgical adhesions, heavy periods (menorrhagia), and benign uterine conditions. Further, the company provides analysis, registration, packaging, production, marketing, sales, and pharmaceutical distribution services to manufacturers worldwide. ATIVA PHARMA S.A. de C.V. was founded in 2010 and is based in Guadalajara, Mexico. As of January 14, 2013, ATIVA PHARMA S.A. de C.V. operates as a subsidiary of Paladin Labs Inc.

Latin America and Caribbean
Health Care Distributors
-
-
-
Labopharm Inc.
Labopharm Inc., a specialty pharmaceutical company, develops drugs by incorporating its proprietary controlled-release technologies worldwide. It offers once-daily formulation of the analgesic tramadol under the RYZOLT brand name for the treatment of patients with moderate to moderately severe pain; Oleptro, a novel once-daily formulation of trazodone for the treatment of major depressive disorder; and twice-daily formulation combining the analgesics tramadol and acetaminophen for the treatment of pain. The company’s novel and proprietary drug delivery technologies include Intellitab technology for the development of abuse-and misuse-deterrent formulations of drugs; polymeric nano-delivery system (PNDS) technology for delivery of water insoluble or poorly bioavailable drugs through administration routes; and Contramid technology for oral administration of soluble to sparingly soluble drugs. Its Intellitab platform product pipeline comprises formulation of oxycodone and acetaminophen; PNDS-based product pipeline consists of novel, lipid, and preservative-free formulation of the intravenous anesthetic propofol; novel oral formulation of SN-38, which is the active metabolite of Irinotecan; and Contramid platform product pipeline includes twice-daily acetaminophen. The company was formerly known as Centre de recherche appliquee pharmaceutique CRAP inc. and changed its name to Labopharm Inc. in September 1994. Labopharm Inc. was founded in 1990 and is headquartered in Laval, Canada. As of October 7, 2011, Labopharm Inc. operates as a subsidiary of Paladin Labs Inc.

United States and Canada
Pharmaceuticals
25.00
32.00
21.00
Bristol-Myers Squibb Company, Tempra(R) line of products
As of February 1, 2011, Tempra(R) line of products of Bristol-Myers Squibb Company was acquired by Paladin Labs Inc. Bristol-Myers Squibb Company, Tempra(R) line of products comprises pediatric brands and manufactures line of products which includes both syrup and drop formulations.

United States and Canada
Pharmaceuticals
-
-
-
Wyeth, Portfolio of Products
As per the transaction announced on June 29, 2009, Portfolio of Products of Wyeth was acquired by Paladin Labs Inc. Wyeth, Portfolio of Products includes over-the-counter pharmaceutical products. The portfolio of products are located in Canada.

United States and Canada
Pharmaceuticals
-
-
-
ViRexx Medical Corp.
As of December 23, 2008, ViRexx Medical Corp. was acquireed by Paladin Labs Inc. ViRexx Medical Corp. develops therapeutic products for the treatment of chronic viral infections and cancer. The company develops therapeutic products based on three technology platforms, which include Chimigen, targeted-autothrombogenic cancer therapy (T-ACT), and antibody-based immunotherapy (AIT). The company’s products using the AIT platform includes OvaRex MAb, a murine antibody-based product that has completed two Phase III clinical trials for the treatment of ovarian cancer; BrevaRex MAb, a murine antibody-based product, which is in Phase II clinical stage for the treatment of breast cancer; ProstaRex MAb that is in pre-clinical trial for the treatment of prostate cancer; and GivaRex MAb, which is in pre-clinical trial for the treatment of pancreatic cancer. Its products from the Chimigen platform include Hepatitis B Therapeutic Vaccine candidate, CHB111, that has completed Phase I clinical trial for the treatment of chronic hepatitis B infection; Hepatitis C Therapeutic Vaccine, which is in pre-clinical stage for the treatment of chronic hepatitis C infection; Avian Influenza vaccines for the treatment of pandemic influenza; biodefense vaccines for the treatment of weaponized biological threat agents; and immune-targeted bionanoparticles. The company’s products from the T-ACT platform include Occlusin 50 Injection that has completed Phase 1 clinical trial for the treatment of primary liver cancer; and Occlusin 500 AED device, which is in pre-clinical trial for the treatment of hypervascular tumors, including uterine fibroids. It has licensing and partnership agreements with Unither Pharmaceuticals, Inc. and Defiante Farmaceutica, Lda., as well as a manufacturing and supply agreement with Tecnogen S.C.p.A. The company is based in Edmonton, Canada.

United States and Canada
Biotechnology
-
1.00
1.00


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Aug-24-2016
Oct-31-2016
Merger/Acquisition
Seller
Telesta Therapeutics Inc.
Prometic Life Sciences Inc. (nka:Liminal BioSciences Inc.)
Paladin Labs Inc.,BL&H Co., Ltd.,Omega Fund Management, LLC,Boxer Capital LLC,Tavistock Life Sciences Seller Funds:Consonance Capital Investors Lp
34.24
Oct-15-2014
Feb-10-2015
Merger/Acquisition
Buyer
Litha Healthcare Group Limited
Paladin Labs Inc.
Visio Capital Management (Pty) Ltd.,Mawer Investment Management Ltd.,Blackstar Fund Managers (Pty) Limited,Jorfect Limited
41.75
Jan-13-2014
Jan-13-2014
Merger/Acquisition
Buyer
Triton Pharma Inc.
Paladin Labs Inc.

-
Nov-5-2013
Feb-28-2014
Merger/Acquisition
Target
Paladin Labs Inc.
Endo International plc (OTCPK:ENDP.Q)
Coller Capital Ltd.,Joddes Limited,Mawer Investment Management Ltd.,Investissement Québec, Investment Arm
1,777.90
Jun-5-2013
Jul-31-2013
Private Placement
Buyer
Telesta Therapeutics Inc.
Paladin Labs Inc.

8.25
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-12-2023
Product-Related Announcements
Paladin Labs Announces Favorable Canadian Agency for Drugs and Technologies in Health Recommendation for XCOPRI (cenobamate tablets)
Jul-31-2023
Bankruptcy - Other
Second Motion for Exclusivity Period Extension Approved For Endo International plc
May-25-2023
Bankruptcy - Filing
Two Affiliate Companies Joined Endo International plc Bankruptcy
Apr-03-2023
Bankruptcy - Other
First Motion for Exclusivity Period Extension Approved For Endo International plc
Jan-09-2023
Company Conference Presentations
Paladin Labs Inc. Presents at BIO Partnering at JPM 2023, Jan-09-2023

M&A Advisors
Blake, Cassels & Graydon LLP, Credit Suisse Securities (USA) LLC, Davies Ward Phillips & Vineberg LLP, Ernst & Young LLP, Nedbank Capital, Werksmans Attorneys Incorporating Jan S. de Villiers


Advisors
Most Recent Auditor
Ernst & Young LLP
M&A Advisors
Blake, Cassels & Graydon LLP, Credit Suisse Securities (USA) LLC, Davies Ward Phillips & Vineberg LLP, Ernst & Young LLP, Nedbank Capital, Werksmans Attorneys Incorporating Jan S. de Villiers
Private Placement Advisors
Davies Ward Phillips & Vineberg LLP
Public Offering Advisors
Davies Ward Phillips & Vineberg LLP, Ernst & Young LLP (Canada)


Most Recent Auditor
Ernst & Young LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
Infinata, Inc.
Infinata Research
Oct 07, 2019 06:42 AM
Paladin Labs Inc.
Paladin Labs, Inc. - Company Report
Reports
10
Infinata, Inc.
Infinata Research
Sep 03, 2019 07:31 AM
Paladin Labs Inc.
Paladin Labs, Inc. - Company Report
Reports
10
Infinata, Inc.
Infinata Research
Jun 03, 2019 05:19 AM
Paladin Labs Inc.
Paladin Labs, Inc. - Company Report
Reports
10
Infinata, Inc.
Infinata Research
Mar 05, 2019 06:32 AM
Paladin Labs Inc.
Paladin Labs, Inc. - Company Report
Reports
8
Infinata, Inc.
Infinata Research
Sep 03, 2018 06:04 AM
Paladin Labs Inc.
Paladin Labs, Inc. - Company Report
Reports
7
Infinata, Inc.
Infinata Research
Jun 18, 2018 07:34 AM
Paladin Labs Inc.
Paladin Labs, Inc. - Company Report
Reports
7
Infinata, Inc.
Infinata Research
Mar 05, 2018 05:10 AM
Paladin Labs Inc.
Paladin Labs, Inc. - Company Report
Reports
7
MarketLine

Feb 20, 2017 06:01 AM
Paladin Labs Inc.
Paladin Labs, Inc. ? Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
Reports
226
MarketLine

Mar 18, 2016 06:01 AM
Paladin Labs Inc.
Paladin Labs, Inc. ? Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
Reports
227
MarketLine

Feb 10, 2016 06:01 AM
Paladin Labs Inc.
Paladin Labs, Inc. ? Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
Reports
225



Top Buyers
No Top Buyers data available.

Top Sellers
Sellers
Common Stock Equivalent Held
Change
Endo International plc
0
(3,543,654)
Joddes Limited
0
(1,078,191)
Water Island Capital, LLC
0
(988,327)
8601135 Canada Inc
0
(839,535)
Davis, Deborah Goodman
0
(591,114)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Actair (Future), Allergens, AmnioSense (Future), Androderm, Antizol, Antizol-Vet, Auragel, Betnesol, Canthacur, Cedocard, Cerumol, Cortifoam, Cyestra-35, Dalacin Vaginal Cream, Darvon-N, Dexedrine, Diacol, DigiFab, Distribution of Abstral, Distribution of APN311 (Future), Distribution of Emtrix, Distribution of Estring, Distribution of Frisium, Distribution of Itine, Distribution of Kaopectate, Distribution of Metadol, Distribution of MOXDUO (Future), Distribution of Pacis, Distribution of Pollinex-R, Distribution of Rectogesic, Distribution of Sabril, Distribution of Sancuso, Distribution of Synera (Future), Distribution of Testim, Distribution of Tostran, Distribution of Travelan, Distribution of Trelstar, Distribution of Tridural, Distribution of Unisom, Distribution of Valtaxin, Distribution of Vicoprofen, Distribution of Xomolix, Dostinex, Duvoid, Dynamiclear Rapid, Elaprase, Estradiol + Testosterone Gel (Future), Estradiol Gel (Future), Fidelin (Future), Florinef, GELICIOUS!, GELMEG3, Glide Octreotide, GlucaGen, Histofreezer, Ibucodone, Impavido (Future), Licensing of Fomepizole, Licensing of Pennsaid, Locacorten Vioform Line, Loestrin, Micro-K Extencaps Capsules, Minestrin, MUSE, Nitrol, Oesclim, Oral Dissolving Teeth Whitening Film Strip (Future), Oralair, Oralair Birch (Future), Oralair Grasses (Future), Oralair Mites (Future), Oxytrol, Pennsaid, Pennsaid Plus (Future), Pharmaceutical Products, Plan B, Pms - Flavoxate, Pms ­ Lithium Carbonate, Pms ­ Selegilene, Pms ­ Tryptophan, Pms ­ Valproic Acid, Pms-Yohimbine, Podofilm, PravASA, Prepidil, Propaderm, Propyl-Thyracil, Prostin, Replagal, Ridaura, RLX030 (Future), Rogitine, Sandomigran, Seasonale, Seasonique, Silenor, Sintrom, Stalair RBet V 1 (Future), Statex, Tapazole, Tempra, Thinsol, Trandate, Twinject Twinpack, Urispas, Urocit-K, VagiSense, Vantas, Veregen Ointment, Voclera (Future), Wartec, Zaditen, Zincofax


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Apr-04-2019
-
Knight Therapeutics Inc. (TSX:GUD)
SEDAR
Management Proxy Materials
5 MB
Apr-04-2019
-
Knight Therapeutics Inc. (TSX:GUD)
SEDAR
News Releases
84 KB
May-24-2018
-
Profound Medical Corp. (TSX:PRN)
SEDAR
Management Proxy Materials
693 KB
Apr-25-2018
Jun-19-2018
Edge Therapeutics, Inc.
SEC
DEF 14A
624 KB
Apr-02-2018
-
Knight Therapeutics Inc. (TSX:GUD)
SEDAR
Management Proxy Materials
1008 KB
Nov-01-2017
Oct-31-2017
Edge Therapeutics, Inc.
SEC
8-K (2.02, 5.02, 8.01, 9.01)
244 KB
Aug-09-2016
Aug-09-2016
Cipher Pharmaceuticals Inc. (TSX:CPH)
SEC
6-K
25 KB
Nov-09-2015
Nov-09-2015
Endo International plc (OTCPK:ENDP.Q)
SEC
8-K (7.01, 9.01)
58 KB
Aug-10-2015
Aug-10-2015
Endo International plc (OTCPK:ENDP.Q)
SEC
8-K (2.02, 9.01)
633 KB
Jun-02-2015
Jun-02-2015
Endo International plc (OTCPK:ENDP.Q)
SEC
8-K (8.01, 9.01)
13 MB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Goodman, Morris 
Feb-19-2014
Common Shares
92,371
-
Other Acquisition
New
Exchange Announcement
Davis, Deborah Goodman
Feb-19-2014
Common Shares
(92,371)
-
Other Disposition
(13.51)
Exchange Announcement
Davis, Deborah Goodman
Feb-19-2014
Common Shares
91,887
-
Private Acquisition
18.41
Exchange Announcement
Davis, Deborah Goodman
Feb-19-2014
Common Shares
(91,887)
-
Private Disposition
(13.45)
Exchange Announcement
Goodman LLB, CFA, David Jason
Feb-18-2014
Common Shares
(190,000)
-
Other Disposition
(100.00)
Exchange Announcement
Excluding Automatic Transactions
Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Di Francesco, Livio
Interim General Manager and Vice President of Finance
514-340-1112
514-344-4675
-
Emblem, Susan Caroline
Vice President of Human Resources and Corporate Communications
514-340-1112
514-344-4675

Trempe, Isabelle
Vice President of Business Development
514-340-1112
514-344-4675
-
* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
